相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium
Lauren Pommert et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases
Shengqin Cheng et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)
Pediatric Acute Myeloid Leukemia-Past, Present, and Future
Dirk Reinhardt et al.
JOURNAL OF CLINICAL MEDICINE (2022)
First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience
Stefanie Kreutmair et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
Seiichiro Katagiri et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?
Cecily Allen et al.
LIFE-BASEL (2021)
Decitabine Induces Gene Derepression on Monosomic Chromosomes: In Vitro and In Vivo Effects in Adverse-Risk Cytogenetics AML
Gabriele Greve et al.
CANCER RESEARCH (2021)
Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia
Myint Myat Khine Aung et al.
MOLECULAR ONCOLOGY (2021)
Emerging Immunotherapy for Acute Myeloid Leukemia
Rikako Tabata et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial
Christoph Roellig et al.
LEUKEMIA (2021)
Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications
Fanny Gonzales et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
Lina Marie Hoffmeister et al.
CANCERS (2021)
IDH Inhibitors in AML-Promise and Pitfalls
Hannah McMurry et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)
Cytogenetic and mutational analysis and outcome assessment of a cohort of 284 children with de novo acute myeloid leukemia reveal complex karyotype as an adverse risk factor for inferior survival
Xi Chen et al.
MOLECULAR CYTOGENETICS (2021)
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
Shirin Hafezi et al.
CANCERS (2021)
Wilms Tumor 1 Mutations Are Independent Poor Prognostic Factors in Pediatric Acute Myeloid Leukemia
Yin Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes
Jasmin Straube et al.
BIOESSAYS (2021)
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
Christian Augsberger et al.
BLOOD (2021)
Molecular Genetics of Pediatric Acute Myeloid Leukemia
Bryan Krock et al.
CLINICS IN LABORATORY MEDICINE (2021)
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
Jessica A. Pollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge
Julie Quessada et al.
GENES (2021)
Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia
Jamie L. Stokke et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Advances in the First Line Treatment of Pediatric Acute Myeloid Leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019
Malgorzata Czogala et al.
CANCERS (2021)
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
Naval Daver et al.
BLOOD CANCER JOURNAL (2021)
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Hitoshi Kiyoi et al.
CANCER SCIENCE (2020)
Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy
Caitlin W. Elgarten et al.
CURRENT OPINION IN PEDIATRICS (2020)
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Group
Richard Aplenc et al.
HAEMATOLOGICA (2020)
Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia: Recent experiences of the Dutch Childhood Oncology Group
Kim Klein et al.
PEDIATRIC BLOOD & CANCER (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Venetoclax is safe and efficacious in relapsed/refractory AML
Chezi Ganzel et al.
LEUKEMIA & LYMPHOMA (2020)
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System
Maria Caterina Rotiroti et al.
MOLECULAR THERAPY (2020)
Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
Hui Zhang et al.
FRONTIERS IN ONCOLOGY (2020)
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
Aaron D. Goldberg et al.
LEUKEMIA RESEARCH (2020)
Characterization of a Novel FLT3 BITE Molecule for the Treatment of Acute Myeloid Leukemia
Bettina Brauchle et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia
Seth E. Karol et al.
CANCER (2020)
Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia
Amanda C. Winters et al.
PEDIATRIC BLOOD & CANCER (2020)
Antibody-Drug Conjugates for Cancer Therapy
Umbreen Hafeez et al.
MOLECULES (2020)
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
Pinar Ataca Atilla et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
Maria Teresa Voso et al.
BLOOD ADVANCES (2020)
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
A. H. Wei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Novel therapies for AML: a round-up for clinicians
Mahesh Swaminathan et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Lina Driouk et al.
FRONTIERS IN IMMUNOLOGY (2020)
Improved Outcome in Pediatric AML - the AML-BFM 2012 Study
Katharina Waack et al.
BLOOD (2020)
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Isha Kapoor et al.
CELL DEATH & DISEASE (2020)
Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
Rebecca Epperly et al.
CHILDREN-BASEL (2020)
An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia
Bing Zheng et al.
CLINICAL CANCER RESEARCH (2019)
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
C. Michel Zwaan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
Juliette Lambert et al.
HAEMATOLOGICA (2019)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial
Jeffrey E. Rubnitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia
Cornelia Hutmacher et al.
LEUKEMIA RESEARCH (2019)
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia
Daniel J. DeAngelo et al.
LEUKEMIA RESEARCH (2019)
Targeted Therapies for Pediatric AML: Gaps and Perspective
Annalisa Lonetti et al.
FRONTIERS IN PEDIATRICS (2019)
HDAC Inhibitors in Acute Myeloid Leukemia
Edurne San Jose-Eneriz et al.
CANCERS (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
Guillermo Garcia-Manero et al.
BLOOD ADVANCES (2019)
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
Andrew E. Place et al.
FUTURE ONCOLOGY (2018)
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies
Tingting Pan et al.
LEUKEMIA RESEARCH (2018)
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
Johanna S. Ungerstedt
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias
Shahzya Chaudhury et al.
NATURE COMMUNICATIONS (2018)
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Regina Jitschin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Yelena Kovtun et al.
BLOOD ADVANCES (2018)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
Alan S. Gamis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
Ursula Creutzig et al.
BLOOD (2012)
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Maria E. Figueroa et al.
CANCER CELL (2010)
Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz et al.
LANCET ONCOLOGY (2010)
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial
J. E. Rubnitz et al.
LEUKEMIA (2009)
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group
Beverly J. Lange et al.
BLOOD (2008)
Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group
TA O'Brien et al.
BLOOD (2002)
Idarubicin improves blast cell clearance during induction therapy in children with AML:: results of study AML-BFM 93
U Creutzig et al.
LEUKEMIA (2001)